Daclizumab Biosimilar, CD25 Monoclonal Antibody

Daclizumab Biosimilar uses the same protein sequences as the therapeutic antibody daclizumab. Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.

Product Details
Species Reactivity	Human
Source	The daclizumab biosimilar CHO stable cell line
Host/Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Immunogen	The human interleukin-2 receptor (anti-Tac or anti-CD25)
Clone	Daclizumab Biosimilar
Conjugate	Unconjugated
Purity	>95%
Molecular Weight	144.24 kDa
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	0.2 uM filtered solution, pH 6.0